Analysts expect Coherus Oncology to announce earnings of ($0.1150) per share and revenue of $14.4060 million for the quarter. Coherus Oncology (NASDAQ:CHRS – Get Free Report) last released its quarterly earnings results on Monday, May 11th. Get Coherus Oncology alerts:Coherus Oncology Stock Down 1.1%Shares of NASDAQ CHRS traded down $0.02 during trading hours on Wednesday, hitting $1.42. Coherus Oncology Company Profile(Get Free Report)Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Featured ArticlesReceive News & Ratings for Coherus Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Oncology and related companies with MarketBeat.com's FREE daily email newsletter.